For the investigation of the antigenic determinant structure of foot-and-mouth disease virus (FMDV), neutralizing monoclonal antibodies (MAbs) against complete virus were characterized by Western blot (immunoblot), enzyme immunoassay, and competition experiments with a synthetic peptide, isolated coat protein VP1, and viral particles as antigens. Two of the four MAbs reacted with each of these antigens, while the other two MAbs recognized only complete viral particles and reacted only very poorly with the peptide. The four MAbs showed different neutralization patterns with a panel of 11 different FMDV strains. cDNA-derived VP1 protein sequences of the different strains were compared to find correlations between the primary structure of the protein and the ability of virus to be neutralized. Based on this analysis, it appears that the first two MAbs recognized overlapping sequential epitopes in the known antigenic site represented by the peptide, whereas the two other MAbs recognized conformational epitopes. These conclusions were supported and extended by structural analyses of FMDV mutants resistant to neutralization by an MAb specific for a conformational epitope. These results demonstrate that no amino acid exchanges had occurred in the primary antigenic site of VP1 but instead in the other coat proteins VP2 and VP3, which by themselves do not induce neutralizing antibodies.
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Foot-and-mouth disease virus (FMDV) belongs to the aphthovirus genus of the family Picornaviridae. Infection with this virus causes a severe, although rarely fatal, disease of cloven-hooved animals. Like other picornaviruses, FMDV possesses a single-stranded positive RNA of about 8,500 nucleotides with a small protein (VPg) covalently bound to its 5' end, an internal poly(C) tract, and a poly(A) sequence at the 3' end (for reviews, see references 1 and 31) . The viral RNA is encapsidated by the four structUral proteins VP1, VP2, VP3, and VP4, which are produced by posttranslational cleavage of a common precursor (32) . Of these, VP1 is of particular interest because immunization studies have shown that this protein harbors the main antigenic determinant for virus neutralization (2, 19) . This major neutralizing antigenic determinant on the virion has been identified as a hexadecapeptide in VP1 (35) . Synthetic peptides containing this hexadecapeptide sequence were able to induce neutralizing antibodies with an efficacy similar to that of VP1 and 12S capsomers (7, 25) . In comparison to whole virions (146S particles), the ability of isolated VP1, 12S subunits, or synthetic peptides to induce neutralizing antibodies is very low. Immunization studies of guinea pigs and cattle with synthetic peptides as antigens have shown that they are fully protective in guinea pigs but not in cattle (7, 11, 26, 27) . To compare the immune response against the synthetic peptides with that against whole virus, neutralizing monoclonal antibodies (MAbs) elicited against viral particles were used for characterization of epitopes important for virus neutralization.
In this report we describe four neutralizing MAbs directed against this major determinant. Two of these recognize continuous epitopes, while the other two recognize conformational epitopes.
MATERIALS AND METHODS
Immunization and production of hybridomas. BALB/c mice were repeatedly injected with a dose of about 50 ,ug of density gradient-purified, ethyleninline-inactivated FMDV strain O1 Kaufbeuren (01K) per mouse at intervals of 3 to 4 weeks. Antigen emulsified in complete Freund adjuvant was used for the first subcutaneous injection and booster injections were done subcutaneously with incomplete Freund adjuvant. After the mice had developed a serum neutralization titer of at least 1:5,000, virus was injected intraperitoneally without adjuvant, and 3 to 4 days later spleens were removed and used for production of hybridomas. Myeloma cells (SP2/0) were used for fusion with spleen cells. (36) . The filters were saturated with 2% BSA dissolved in PBS (150 mM NaCl, 10 mM sodium phosphate, pH 7.5) for 2 h to prevent nonspecific protein binding, followed by incubation with a 1:1,000 dilution of ascites fluid or antiserum (2% BSA and 0.05% NP40 in PBS) for at least 12 h. Parallel incubations with antisera or ascites, also diluted 1:1,000, which were previously allowed to react with an excess of the synthetic peptide (10 ,ug), were also carried out. After several washes, the binding of specific antibodies was monitored by incubation with 1251-labeled rabbit antimouse or goat anti-rabbit immunoglobulins (both from Amersham-Buchler, Braunschweig, FRG) for 2 h. The immune reaction was visualized by autoradiography.
Isolation of neutralization-resistant mutants. Antigenic variants of 01K, 64th passage, pretreated with antibody were selected on BHK cells by plaque formation under a methylcellulose overlay which also contained the antibody. Putative mutants were subjected to another cycle of selection.
Isolation of viral RNA, cDNA synthesis, and sequencing analysis of the coat protein region. Virus preparations were grown in BHK cells and purified by the method of Strohmaier et al. (35) . The viral proteins were extracted twice with neutralized 80% (wt/wt) phenol and once with chloroformisoamyl alcohol (24:1), and the RNA was precipitated with 2 volumes of ethanol and stored in aliquots at -70°C. Eight primer oligonucleotides were synthesized by the phosphoamidite method (9) with an automated oligonucleotide synthesiser (Applied Biosystems 380A). The selected oligonucleotides were complementary to sequences most conserved between different serotypes and correspond to positions in the 01K coat protein region 238 to 260, 549 to 568, 914 to 932, 1143 to 1163, 1350 to 1372, 1723 to 1746, and 2006 to 2027 and in addition a 20-mer oligonucleotide starting 6 nucleotides past the 3' end of the VP1 gene. Synthesis of cDNA and the sequence analysis were performed as described (6). In addition, direct RNA sequencing was performed for a few primers by the method of Zimmern and Kaesberg (38) as modified by Palmenberg et al. (23) .
RESULTS
Immunological characterization of the MAbs. Neutralizing MAbs were raised against intact FMDV strain 01K (146S particles). Four MAbs with high neutralizing titers were obtained and tested in an indirect ELISA for their ability to bind to whole virus, 12S subunits, isolated VP1, VP2, and VP3, and synthetic peptides A (amino acids [aa] 144 to 159), G1-21 (aa 140 to 160), and G1-32 (aa 129 to 160) (Fig. 1) . The MAbs used and their immunological characteristics are shown in Fig. 2 . MAbs 7 and 48 recognized only intact 146S particles and to a minor extent the shorter synthetic peptides A and G1-21, whereas MAbs 75 and 99 reacted with intact 146S particles as well as with the 12S subunit, isolated VP1, and the three synthetic peptides. In no case was a reaction observed with VP2 or VP3.
The reactivity of the MAbs against the four denatured viral capsid proteins was analyzed in a Western blot (Fig. 3) . Polyclonal rabbit antisera elicited by isolated viral proteins VP1, VP2, and VP3 and by synthetic peptide A were used as positive controls. MAbs 7 and 48 did not react with any of the viral proteins, whereas MAbs 75 and 99 recognized the VP1 protein (Fig. 3 ). The specificity of this immune reaction was confirmed by the fact that binding of the antibodies could be inhibited by preincubation with synthetic peptide G1-21, which is part of VP1.
Similar results were obtained in a competition ELISA with the viral coat proteins and the synthetic peptide used as competitors (Fig. 4) . In this assay, the antibody binding of MAbs 7 and 48 could also be measured, because intact viral particles were used as an antigen. The antibodies were preincubated with the different coat proteins or synthetic peptides, and the remaining binding capacity was measured. As a control, intact viral particles were used as the competing antigen.
The results (Fig. 4) demonstrate that VP1 and peptide A clearly competed with 146S particles for binding to MAbs 75 and 99. This is in accord with the data from the Western blots and localizes the antibody-binding sites for these two MAbs between aa 144 and 159. In the case of MAbs 7 and 48, no significant competition was observed with the isolated coat proteins VP1 (Fig. 4) specific for certain 0 isolates but showed distinct differences. MAb 7 neutralized its homologous strain 01K and also O1BFS and 0 Israel, which is presently not classified into a subtype. It did not neutralize O1Lausanne (01L), O1Murchin, or O1Danemark. In contrast, MAb 48 neutralized 01K, O1BFS, 01L, O1Murchin, and O1Danemark, but not 0 Israel. From these neutralization patterns, it appears that these MAbs recognize four different epitopes on the virus surface.
Sequence comparison of FMDV strains tested in the plaque reduction assay. We compared changes in the cDNA-derived amino acid sequence of coat protein VP1 of all strains tested to correlate the different binding specificities of the MAbs with the amino acid sequence of coat protein VP1. A list of the amino acid sequences of all 0 strains tested (4, 6, 17, 20, 29) indicates that the five isolates 01K, 01BFS, 01L, O1Murchin, and O1Danemark showed only minor differences in their sequences (Fig. 5A) O1Kaufbeuren O1Lausanne O1K virus pool. Thus, the four mutants selected from FMDV O1K showed a neutralization pattern identical to that of FMDV 01L. For two of these mutants, the relevant changes leading to an escape from MAb 7 neutralization were characterized in detail by cDNA sequencing of the coat protein P1 coding region except for the first 50 amino acids of VP4. Both mutants had the same nucleotide sequence. By comparison of the deduced amino acid sequence with that of the original strain 01K (5), no differences were detected in VP1 or the sequenced part of VP4, but two exchanges in VP2 sequence. A partial sequence analysis of the coat protein region of the parent strain used for the selection of the antibody-resistant mutants showed that in the majority of the virions, a cysteine was present at aa 200. Therefore it seems that normally a cysteine is present in this position in all 01 subtypes and that the cloned and sequenced 01K genome (5) represents only a minority of the FMDV virions in the parent strain.
DISCUSSION
By characterizing four MAbs elicited by whole FMDV, we provide evidence for the presence of four different epitopes on the viral surface that are involved in virus neutralization. Two of these epitopes are linear and are part of the previously identified major antigenic site, a hexadecapeptide between aa 144 and 159 in coat protein VP1 which is able to induce neutralizing antibodies in animals (7, 11, (25) (26) (27) almost all amino acid exchanges within the FMDV 0 serotype are located on the hydrophobic part of the helix (Fig. 7) . Such exchanges had no influence on the efficacy of neutralization by MAb 99, in contrast to exchanges on the hydrophilic side, which affected neutralization by MAb 99 but not by MAb 75. Therefore, the possibility that the secondary structure of VP1 influences the MAb 99 epitope cannot be excluded.
Geysen et al. (13) (Fig. 2) , in which the short peptides A and G1-21 were recognized by MAbs 7 and 48 but peptide G1-32 and coat protein VP1 were not. This observation is probably related to the loss of conformational flexibility in the longer polypeptides.
Sequence analyses of the coat proteins VP1, VP2, and VP3 and a part of VP4 of 01L and 01K mutants resistant to MAb 7 led to the conclusion that both of the other major coat proteins, VP2 and VP3, are most likely involved in the formation of the epitope structure recognized by MAb 7. Amino acid exchanges correlated with antibody resistance were found only in VP2 and VP3 and within the same region or even in the same position in the sequenced strain 01L and the mutants. A computer-derived three-dimensional model for FMDV that is based on the known structure of the human rhinovirus type indicates that the regions in VP2 and VP3 in which amino acid exchanges occurred are physically close to the major antigenic site in VP1 (R. (Fig. 7) . Thus, the amino acid in position 144 or 155 is important for the epitope recognized by MAb 48.
As shown previously for FMDV and other picornaviruses, conformation-dependent epitopes are important for virus neutralization (3, 12, 14, 15, 21, 24, 34) . In the cases for HRV-14 and poliovirus type 1, binding sites of neutralizing antibodies have also been mapped by inhibition with synthetic peptides and sequence analysis of neutralizationresistant mutants selected by neutralizing MAbs and involve capsid proteins VP1, VP2, and VP3 or combinations of these polypeptides (8, 10, 33) . These results have been confirmed by the three-dimensional structure of HRV-14 (28) and poliovirus type 1 (16) .
In summary, we have shown for the first time that structural proteins other than VP1 are involved in neutralization of FMDV. The information obtained from mapping the different epitopes involved in FMDV neutralization could be used to gain an understanding of the humoral and cellular immune response mounted against FMDV infection and to formulate potential new vaccines from either synthetic peptides or recombinant proteins. The neutralizing epitopes mapped with murine MAbs should be verified with MAbs produced from bovine spleen cells, because, as has been shown for poliovirus, epitopes recognized by the murine immune system are not necessarily recognized by the natural host's immune system (10) .
